Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Astragaloside VI could improve wound healing by activating the EGFR/ERK signaling pathway.
In vitro | Pretreatment with Astragaloside VI (1 μM) enhances EGFR activation in HaCaT cells and significantly promotes cell proliferation in both HaCaT and HDF cells. As a principal intestinal metabolite of astragalosides, Astragaloside VI is the most potent in stimulating EGFR activation. Furthermore, it is comparable to the positive control, EGF, which is known to increase cell proliferation by 1.5 times in HaCaT cells. Additionally, Astragaloside VI facilitates neural stem cell proliferation and improves neurological function recovery following transient cerebral ischemic injury through the activation of EGFR/MAPK signaling pathways [1] [2]. |
分子量 | 947.122 |
分子式 | C47H78O19 |
CAS No. | 84687-45-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Astragaloside VI 84687-45-6 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR Inhibitor inhibitor inhibit